Primary Cutaneous Melanoma—Management in 2024

Anthony Joseph Dixon,Michael Sladden,Christos C. Zouboulis,Catalin M. Popescu,Alexander Nirenberg,Howard K. Steinman,Caterina Longo,Zoe Lee Dixon,Joseph Meirion Thomas

DOI: https://doi.org/10.3390/jcm13061607

IF: 3.9

2024-03-12

Journal of Clinical Medicine

Abstract:Background: Maximizing survival for patients with primary cutaneous melanomas (melanomas) depends on an early diagnosis and appropriate management. Several new drugs have been shown to improve survival in high-risk melanoma patients. Despite well-documented guidelines, many patients do not receive optimal management, particularly when considering patient age. Objective: to provide an update on melanoma management from the time of the decision to biopsy a suspicious skin lesion. Methods: We reviewed melanoma-management research published between 2018 and 2023 and identified where such findings impact and update the management of confirmed melanomas. Pubmed, Google Scholar, Ovid and Cochrane Library were used as search tools. Results: We identified 81 publications since 2017 that have changed melanoma management; 11 in 2018, 12 in 2019, 10 in 2020, 12 in 2021, 17 in 2022 and 18 in 2023. Discussion: Delayed or inaccurate diagnosis is more likely to occur when a partial shave or punch biopsy is used to obtain the histopathology. Wherever feasible, a local excision with a narrow margin should be the biopsy method of choice for a suspected melanoma. The Breslow thickness of the melanoma remains the single most important predictor of outcome, followed by patient age and then ulceration. The BAUSSS biomarker, (Breslow thickness, Age, Ulceration, Subtype, Sex and Site) provides a more accurate method of determining mortality risk than older currently employed approaches, including sentinel lymph node biopsy. Patients with metastatic melanomas and/or nodal disease should be considered for adjuvant drug therapy (ADT). Further, high-risk melanoma patients are increasingly considered for ADT, even without disease spread. Invasive melanomas less than 1 mm thick are usually managed with a radial excision margin of 10 mms of normal skin. If the thickness is 1 to 2 mm, select a radial margin of 10 to 20 mm. When the Breslow thickness is over 2 mm, a 20 mm clinical margin is usually undertaken. In situ melanomas are usually managed with a 5 to 10 mm margin or Mohs margin control surgery. Such wide excisions around a given melanoma is the only surgery that can be regarded as therapeutic and required. Patients who have had one melanoma are at increased risk of another melanoma. Ideal ongoing management includes regular lifelong skin checks. Total body photography should be considered if the patient has many naevi, especially when atypical/dysplastic naevi are identified. Targeted approaches to improve occupational or lifestyle exposure to ultraviolet light are important. Management also needs to include the consideration of vitamin D supplementary therapy.

medicine, general & internal

What problem does this paper attempt to address?

The main issue this paper attempts to address is improving the survival rate of patients with primary cutaneous melanomas. To achieve this goal, the paper focuses on the following aspects:

1. **Early Diagnosis and Proper Management**: Emphasizes the importance of early diagnosis in improving survival rates and discusses melanoma management methods starting from the decision to biopsy suspicious skin lesions.

2. **Updated Management Strategies**: Reviews studies published from 2018 to 2023, identifying how these studies have influenced and updated the management methods for diagnosed melanomas.

3. **Biopsy Techniques**: Discusses the most appropriate biopsy methods, particularly the advantages of excisional biopsy (EB) over partial shave or punch biopsies to reduce the risk of misdiagnosis.

4. **Surgical Margins**: Provides recommended surgical margins for different Breslow thicknesses to ensure complete tumor removal.

5. **Adjuvant Drug Therapy (ADT)**: Explores the possibility of using adjuvant drug therapy in high-risk patients, even in the absence of disease spread.

6. **Role of Sentinel Lymph Node Biopsy (SLNB)**: Evaluates the role of SLNB in melanoma management, particularly its applicability and limitations in patients of different age groups.

7. **BAUSSS Biomarkers**: Introduces BAUSSS (Breslow thickness, Age, Ulceration, Subtype, Sex, and Site) as a more accurate method for predicting mortality risk. Compared to traditional SLNB, BAUSSS provides better prognostic information.

Through the discussion of these aspects, the paper aims to provide clinicians with the latest melanoma management guidelines to optimize patient treatment outcomes and survival rates.